A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

• Status: RECRUITING
• Trial end date: 2028-02-01

Summary

The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.

Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.

• Phase: PHASE2

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: abemaciclib; Temozolomide